Gerrit Storm

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9238515/publications.pdf

Version: 2024-02-01

398 papers	32,125 citations	2970 93 h-index	5986 160 g-index
400 all docs	400 docs citations	400 times ranked	34548 citing authors

#	Article	IF	Citations
1	Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. Drug Delivery and Translational Research, 2022, 12, 7-14.	3.0	3
2	Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. Journal of Controlled Release, 2022, 341, 475-486.	4.8	66
3	Incorporation of Toll-Like Receptor Ligands and Inflammasome Stimuli in GM3 Liposomes to Induce Dendritic Cell Maturation and T Cell Responses. Frontiers in Immunology, 2022, 13, 842241.	2.2	7
4	The Effect of Microbubble-Assisted Ultrasound on Molecular Permeability across Cell Barriers. Pharmaceutics, 2022, 14, 494.	2.0	6
5	Src kinase as a potential therapeutic target in nonâ€alcoholic and alcoholic steatohepatitis. Clinical and Translational Discovery, 2022, 2, .	0.2	1
6	A review of the clinical applications of drug delivery systems for the treatment of ocular anterior segment inflammation. British Journal of Ophthalmology, 2021, 105, 1617-1622.	2.1	10
7	Î electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. Biomaterials, 2021, 266, 120432.	5.7	31
8	Treatment Outcome Measurement Instruments for Port Wine Stains: A Systematic Review of Their Measurement Properties. Dermatology, 2021, 237, 416-432.	0.9	7
9	Lyophilization stabilizes clinicalâ€stage coreâ€crosslinked polymeric micelles to overcome cold chain supply challenges. Biotechnology Journal, 2021, 16, e2000212.	1.8	17
10	Mimicking Pathogens to Augment the Potency of Liposomal Cancer Vaccines. Pharmaceutics, 2021, 13, 954.	2.0	7
11	A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system. Drug Discovery Today, 2021, 26, 1482-1489.	3.2	12
12	Nanomedicine at the crossroads â€“ A quick guide for IVIVC. Advanced Drug Delivery Reviews, 2021, 179, 113829.	6.6	29
13	CD169 Defines Activated CD14+ Monocytes With Enhanced CD8+ T Cell Activation Capacity. Frontiers in Immunology, 2021, 12, 697840.	2.2	33
14	Lyophilization Preserves the Intrinsic Cardioprotective Activity of Bioinspired Cell-Derived Nanovesicles. Pharmaceutics, 2021, 13, 1052.	2.0	9
15	Extracellular vesicles as a drug delivery system: A systematic review of preclinical studies. Advanced Drug Delivery Reviews, 2021, 175, 113801.	6.6	92
16	Therapeutic and diagnostic targeting of fibrosis in metabolic, proliferative and viral disorders. Advanced Drug Delivery Reviews, 2021, 175, 113831.	6.6	17
17	Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo. Journal of Controlled Release, 2021, 337, 521-529.	4.8	36
18	Liposomal Nanovaccine Containing Î±-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1. Vaccines, 2021, 9, 56.	2.1	20

#	Article	IF	Citations
19	Ultrasound and Microbubbles for the Treatment of Ocular Diseases: From Preclinical Research towards Clinical Application. Pharmaceutics, 2021, 13, 1782.	2.0	10
20	Photodynamic Therapy Targeting Macrophages Using IRDye700DX-Liposomes Decreases Experimental Arthritis Development. Pharmaceutics, 2021, 13, 1868.	2.0	5
21	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of ⁸⁹Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. Bioconjugate Chemistry, 2020, 31, 360-368.	1.8	22
22	FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor. Nanotheranostics, 2020, 4, 26-39.	2.7	30
23	Transferrin-binding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. Journal of Controlled Release, 2020, 319, 407-415.	4.8	74
24	The role of liposomes in clinical nanomedicine development. What now? Now what?. Journal of Controlled Release, 2020, 318, 256-263.	4.8	226
25	High-resolution 3D visualization of nanomedicine distribution in tumors. Theranostics, 2020, 10, 880-897.	4.6	13
26	Fibroblast growth factor 2 conjugated superparamagnetic iron oxide nanoparticles (FGF2-SPIONs) ameliorate hepatic stellate cells activation in vitro and acute liver injury in vivo. Journal of Controlled Release, 2020, 328, 640-652.	4.8	35
27	Selective tumor antigen vaccine delivery to human CD169 ⁺ antigen-presenting cells using ganglioside-liposomes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27528-27539.	3.3	54
28	Optical imaging of the whole-body to cellular biodistribution of clinical-stage PEG-b-pHPMA-based core-crosslinked polymeric micelles. Journal of Controlled Release, 2020, 328, 805-816.	4.8	30
29	Optimization of Liposomes for Antigen Targeting to Splenic CD169+ Macrophages. Pharmaceutics, 2020, 12, 1138.	2.0	15
30	Dexamethasone nanomedicines for COVID-19. Nature Nanotechnology, 2020, 15, 622-624.	15.6	138
31	Complete Tumor Regression by Liposomal Bortezomib in a Humanized Mouse Model of Multiple Myeloma. HemaSphere, 2020, 4, e463.	1.2	5
32	Apoptosis-inducing peptide loaded in PLGA nanoparticles induces anti-tumor effects in vivo. International Journal of Pharmaceutics, 2020, 585, 119535.	2.6	9
33	Therapeutic Efficacy of Novel Antimicrobial Peptide AA139-Nanomedicines in a Multidrug-Resistant Klebsiella pneumoniae Pneumonia-Septicemia Model in Rats. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	14
34	Cancer nanomedicine meets immunotherapy: opportunities and challenges. Acta Pharmacologica Sinica, 2020, 41, 954-958.	2.8	33
35	In Vivo Assessment of Thermosensitive Liposomes for the Treatment of Port Wine Stains by Antifibrinolytic Site-Specific Pharmaco-Laser Therapy. Pharmaceutics, 2020, 12, 591.	2.0	2
36	The hepatic lipidome: From basic science to clinical translation. Advanced Drug Delivery Reviews, 2020, 159, 180-197.	6.6	37

#	Article	IF	Citations
37	Clinical outcome measures and scoring systems used in prospective studies of port wine stains: A systematic review. PLoS ONE, 2020, 15, e0235657.	1.1	17
38	Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation. Theranostics, 2020, 10, 1948-1959.	4.6	30
39	Systematic evaluation of design features enables efficient selection of Î electron-stabilized polymeric micelles. International Journal of Pharmaceutics, 2020, 584, 119409.	2.6	11
40	Role of spleen tyrosine kinase in liver diseases. World Journal of Gastroenterology, 2020, 26, 1005-1019.	1.4	16
41	Liposome-induced hypersensitivity reactions: Risk reduction by design of safe infusion protocols in pigs. Journal of Controlled Release, 2019, 309, 333-338.	4.8	36
42	Cyclic RGD-Functionalized and Disulfide-Crosslinked Iodine-Rich Polymersomes as a Robust and Smart Theranostic Agent for Targeted CT Imaging and Chemotherapy of Tumor. Theranostics, 2019, 9, 8061-8072.	4.6	34
43	Scale-Up of the Manufacturing Process To Produce Docetaxel-Loaded mPEG-b-p(HPMA-Bz) Block Copolymer Micelles for Pharmaceutical Applications. Organic Process Research and Development, 2019, 23, 2707-2715.	1.3	9
44	Shelf-Life Evaluation and Lyophilization of PBCA-Based Polymeric Microbubbles. Pharmaceutics, 2019, 11, 433.	2.0	17
45	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Science Advances, 2019, 5, eaax2770.	4.7	81
46	Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 17, 106-118.	1.7	28
47	Liposomal dexamethasone inhibits tumor growth in an advanced human-mouse hybrid model of multiple myeloma. Journal of Controlled Release, 2019, 296, 232-240.	4.8	27
48	TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo. FASEB Journal, 2019, 33, 9466-9475.	0.2	16
49	Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Acta Biomaterialia, 2019, 92, 196-204.	4.1	40
50	Liver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo. Biomaterials, 2019, 206, 49-60.	5.7	22
51	Development and characterization of liposomal formulation of bortezomib. International Journal of Pharmaceutics: X, 2019, 1, 100011.	1.2	13
52	Site-specific pharmaco-laser therapy: A novel treatment modality for refractory port wine stains. Journal of Clinical and Translational Research, 2019, 5, 1-24.	0.3	10
53	Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer. Cancer Letters, 2018, 420, 247-258.	3.2	55
54	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. Journal of Controlled Release, 2018, 277, 1-13.	4.8	214

#	Article	IF	Citations
55	Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. Biomaterials, 2018, 178, 481-495.	5.7	50
56	Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery. Advanced Drug Delivery Reviews, 2018, 129, 37-53.	6.6	145
57	Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis. Rheumatology, 2018, 57, 737-747.	0.9	22
58	Critical evaluation of quantification methods for oligonucleotides formulated in lipid nanoparticles. International Journal of Pharmaceutics, 2018, 548, 793-802.	2.6	7
59	Histidine-rich glycoprotein-induced vascular normalization improves EPR-mediated drug targeting to and into tumors. Journal of Controlled Release, 2018, 282, 25-34.	4.8	29
60	Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis. Scientific Reports, 2018, 8, 6604.	1.6	33
61	Targeting the Stat6 pathway in tumorâ€associated macrophages reduces tumor growth and metastatic niche formation in breast cancer. FASEB Journal, 2018, 32, 969-978.	0.2	134
62	E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells. International Journal of Pharmaceutics, 2018, 548, 759-770.	2.6	31
63	Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information. Journal of Controlled Release, 2018, 270, 268-274.	4.8	36
64	Inhibition of canonical WNT signaling pathway by Î²-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 804-818.	1.8	73
65	Influence of cholesterol inclusion on the doxorubicin release characteristics of lysolipid-based thermosensitive liposomes. International Journal of Pharmaceutics, 2018, 548, 778-782.	2.6	30
66	Sonopermeation to improve drug delivery to tumors: from fundamental understanding to clinical translation. Expert Opinion on Drug Delivery, 2018, 15, 1249-1261.	2.4	76
67	Antibiotic-nanomedicines: facing the challenge of effective treatment of antibiotic-resistant respiratory tract infections. Future Microbiology, 2018, 13, 1683-1692.	1.0	13
68	Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo. Journal of Controlled Release, 2018, 290, 1-10.	4.8	88
69	Granzyme B-loaded, cell-selective penetrating and reduction-responsive polymersomes effectively inhibit progression of orthotopic human lung tumor in vivo. Journal of Controlled Release, 2018, 290, 141-149.	4.8	52
70	Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. Journal of Controlled Release, 2018, 288, 227-238.	4.8	37
71	Environmental impact of switching from the synthetic glucocorticoid prednisolone to the natural alkaloid berberine. PLoS ONE, 2018, 13, e0199095.	1.1	7
72	From design to the clinic: practical guidelines for translating cardiovascular nanomedicine. Cardiovascular Research, 2018, 114, 1714-1727.	1.8	63

#	Article	IF	Citations
73	Current Trends and Challenges in the Clinical Translation of Nanoparticulate Nanomedicines: Pathways for Translational Development and Commercialization. Frontiers in Pharmacology, 2018, 9, 790.	1.6	586
74	Preclinical evaluation of thermosensitive poly(N-(2-hydroxypropyl) methacrylamide) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 Td (mono Pharmaceutics, 2018, 550, 190-199.	2.6	9
75	Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Advanced Drug Delivery Reviews, 2017, 108, 25-38.	6.6	881
76	The battle of â€œnanoâ€•paclitaxel. Advanced Drug Delivery Reviews, 2017, 122, 20-30.	6.6	270
77	Applying nanomedicine in maladaptive inflammation and angiogenesis. Advanced Drug Delivery Reviews, 2017, 119, 143-158.	6.6	46
78	Anti-microRNA targeting using peptide-based nanocomplexes to inhibit differentiation of human pancreatic stellate cells. Nanomedicine, 2017, 12, 1369-1384.	1.7	31
79	Tyrosine kinase inhibitor BIBF1120 ameliorates inflammation, angiogenesis and fibrosis in CCl4-induced liver fibrogenesis mouse model. Scientific Reports, 2017, 7, 44545.	1.6	39
80	Nanopolymersomes with an Ultrahigh Iodine Content for Highâ€Performance Xâ€Ray Computed Tomography Imaging In Vivo. Advanced Materials, 2017, 29, 1603997.	11.1	70
81	Liposome encapsulated berberine treatment attenuates cardiac dysfunction after myocardial infarction. Journal of Controlled Release, 2017, 247, 127-133.	4.8	104
82	Lipogels responsive to near-infrared light for the triggered release of therapeutic agents. Acta Biomaterialia, 2017, 61, 54-65.	4.1	14
83	The role of thromboxane A2 in complement activation-related pseudoallergy. European Journal of Nanomedicine, 2017, 9, .	0.6	1
84	Integrin alpha 11 in the regulation of the myofibroblast phenotype: implications for fibrotic diseases. Experimental and Molecular Medicine, 2017, 49, e396-e396.	3.2	61
85	Bioinspired Cell-Derived Nanovesicles versus Exosomes as Drug Delivery Systems: a Cost-Effective Alternative. Scientific Reports, 2017, 7, 14322.	1.6	146
86	A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis. Journal of Controlled Release, 2017, 262, 47-57.	4.8	44
87	Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors. Advanced Drug Delivery Reviews, 2017, 119, 44-60.	6.6	194
88	Targeting distinct myeloid cell populations inÂvivo using polymers, liposomes and microbubbles. Biomaterials, 2017, 114, 106-120.	5.7	63
89	Physicoâ€Chemical Strategies to Enhance Stability and Drug Retention of Polymeric Micelles for Tumorâ€Targeted Drug Delivery. Macromolecular Bioscience, 2017, 17, 1600160.	2.1	125
90	Liposomal Treatment of Experimental Arthritis Can Be Monitored Noninvasively with a Radiolabeled Antiâ€“Fibroblast Activation Protein Antibody. Journal of Nuclear Medicine, 2017, 58, 151-155.	2.8	32

#	Article	IF	Citations
91	Nanomedicine Strategies to Target Tumor-Associated Macrophages. International Journal of Molecular Sciences, 2017, 18, 979.	1.8	79
92	Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget, 2016, 7, 3341-3356.	0.8	56
93	Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: an in vitro assessment. International Journal of Nanomedicine, 2016, Volume 11, 5027-5040.	3.3	40
94	MicroRNA Targeting to Modulate Tumor Microenvironment. Frontiers in Oncology, 2016, 6, 3.	1.3	108
95	Head-to-Head Comparison of Anti-Inflammatory Performance of Known Natural Products In Vitro. PLoS ONE, 2016, 11, e0155325.	1.1	20
96	Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications. Journal of Controlled Release, 2016, 244, 314-325.	4.8	37
97	Radionuclide imaging of liposomal drug delivery. Expert Opinion on Drug Delivery, 2016, 13, 1231-1242.	2.4	41
98	High systemic availability of core-crosslinked polymeric micelles after subcutaneous administration. International Journal of Pharmaceutics, 2016, 514, 112-120.	2.6	7
99	The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Scientific Reports, 2016, 5, 18272.	1.6	70
100	Multiple pathway assessment to predict anti-atherogenic efficacy of drugs targeting macrophages in atherosclerotic plaques. Vascular Pharmacology, 2016, 82, 51-59.	1.0	8
101	Comparison of pharmaceutical nanoformulations for curcumin: Enhancement of aqueous solubility and carrier retention. International Journal of Pharmaceutics, 2016, 506, 407-413.	2.6	29
102	Liposomal doxorubicin: the good, the bad and the not-so-ugly. Journal of Drug Targeting, 2016, 24, 765-767.	2.1	11
103	Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. Trends in Pharmacological Sciences, 2016, 37, 451-462.	4.0	45
104	Increase of intracellular cisplatin levels and radiosensitization by ultrasound in combination with microbubbles. Journal of Controlled Release, 2016, 238, 157-165.	4.8	38
105	Targeting cellular and microenvironmental multidrug resistance. Expert Opinion on Drug Delivery, 2016, 13, 1199-1202.	2.4	9
106	Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration. Journal of Controlled Release, 2016, 244, 257-268.	4.8	119
107	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6731-E6740.	3.3	95
108	Ultrasound-mediated drug delivery to the brain: principles, progress and prospects. Drug Discovery Today: Technologies, 2016, 20, 41-48.	4.0	120

#	Article	IF	Citations
109	Cancer nanomedicine: is targeting our target?. Nature Reviews Materials, 2016, 1, .	23.3	154
110	Liposomal prednisolone inhibits tumor growth in a spontaneous mouse mammary carcinoma model. Journal of Controlled Release, 2016, 243, 243-249.	4.8	14
111	Differential uptake of nanoparticles by human M1 and M2 polarized macrophages: protein corona as a critical determinant. Nanomedicine, 2016, 11, 2889-2902.	1.7	63
112	Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. International Journal of Pharmaceutics, 2016, 499, 358-367.	2.6	207
113	Sonoporation enhances liposome accumulation and penetration in tumors with low EPR. Journal of Controlled Release, 2016, 231, 77-85.	4.8	119
114	Locoregional cancer therapy using polymer-based drug depots. Drug Discovery Today, 2016, 21, 640-647.	3.2	25
115	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocrine-Related Cancer, 2016, 23, 35-45.	1.6	49
116	Ligand-targeted Particulate Nanomedicines Undergoing Clinical Evaluation: Current Status. Fundamental Biomedical Technologies, 2016, , 163-200.	0.2	16
117	MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor. Oncotarget, 2016, 7, 16396-16408.	0.8	72
118	Alginate Microspheres Containing Temperature Sensitive Liposomes (TSL) for MR-Guided Embolization and Triggered Release of Doxorubicin. PLoS ONE, 2015, 10, e0141626.	1.1	25
119	Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo. PLoS ONE, 2015, 10, e0128466.	1.1	7
120	Sonochemotherapy: from bench to bedside. Frontiers in Pharmacology, 2015, 6, 138.	1.6	84
121	Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 2015, 23, 103-131.	5.6	104
122	Pharmaceutical development and preclinical evaluation of a GMP-grade anti-inflammatory nanotherapy. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1133-1140.	1.7	37
123	Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo. Prostate, 2015, 75, 815-824.	1.2	41
124	Comparison of three remote radiolabelling methods for long-circulating liposomes. Journal of Controlled Release, 2015, 220, 239-244.	4.8	23
125	Distribution of technetium-99m PEG-liposomes during oligofructose-induced laminitis development in horses. Veterinary Journal, 2015, 206, 218-225.	0.6	4
126	Theranostic USPIOâ€Loaded Microbubbles for Mediating and Monitoring Bloodâ€Brain Barrier Permeation. Advanced Functional Materials, 2015, 25, 36-43.	7.8	123

#	Article	IF	Citations
127	Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens. Journal of Controlled Release, 2015, 203, 67-76.	4.8	68
128	Hybrid Materials: Theranostic USPIOâ€Loaded Microbubbles for Mediating and Monitoring Bloodâ€Brain Barrier Permeation (Adv. Funct. Mater. 1/2015). Advanced Functional Materials, 2015, 25, 2-2.	7.8	6
129	Development of a tumor tissue-mimicking model with endothelial cell layer and collagen gel for evaluating drug penetration. International Journal of Pharmaceutics, 2015, 482, 118-122.	2.6	7
130	Atherosclerotic Plaque Targeting Mechanism of Long-Circulating Nanoparticles Established by Multimodal Imaging. ACS Nano, 2015, 9, 1837-1847.	7.3	105
131	A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles. Journal of Controlled Release, 2015, 205, 98-108.	4.8	30
132	Duration of ultrasound-mediated enhanced plasma membrane permeability. International Journal of Pharmaceutics, 2015, 482, 92-98.	2.6	49
133	In situ Delivery of Tumor Antigenâ€“ and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells. Journal of Investigative Dermatology, 2015, 135, 2697-2704.	0.3	25
134	Liposomes: The Science and the Regulatory Landscape. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 77-106.	0.2	10
135	Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects. Chemical Reviews, 2015, 115, 10907-10937.	23.0	401
136	Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs. Biochemical and Biophysical Research Communications, 2015, 468, 490-497.	1.0	81
137	MPLA incorporation into DC-targeting glycoliposomes favours anti-tumour T cell responses. Journal of Controlled Release, 2015, 216, 37-46.	4.8	64
138	Image-guided drug delivery: preclinical applications and clinical translation. Expert Opinion on Drug Delivery, 2015, 12, 1203-1207.	2.4	38
139	[18]F FDG PET/CT imaging to monitor the therapeutic effect of liposome-encapsulated prednisolone in experimental rheumatoid arthritis. Journal of Controlled Release, 2015, 209, 20-26.	4.8	23
140	Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1039-1046.	1.7	127
141	Complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles. Biomaterials, 2015, 53, 370-378.	5.7	88
142	In situ Delivery of Antigen to DC-SIGN + CD14 + Dermal Dendritic Cells Results in Enhanced CD8 + T-Cell Responses. Journal of Investigative Dermatology, 2015, 135, 2228-2236.	0.3	35
143	Fluorophore labeling of core-crosslinked polymeric micelles for multimodal in vivo and ex vivo optical imaging. Nanomedicine, 2015, 10, 1111-1125.	1.7	17
144	Complete Regression of Xenograft Tumors upon Targeted Delivery of Paclitaxel via Îâ€“Î Stacking Stabilized Polymeric Micelles. ACS Nano, 2015, 9, 3740-3752.	7.3	185

#	Article	IF	Citations
145	Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Science Advances, 2015, 1, .	4.7	173
146	Alginate microgels loaded with temperature sensitive liposomes for magnetic resonance imageable drug release and microgel visualization. European Polymer Journal, 2015, 72, 620-631.	2.6	20
147	Fluorescent cell-traceable dexamethasone-loaded liposomes for the treatment of inflammatory liver diseases. Biomaterials, 2015, 37, 367-382.	5.7	115
148	Superoxide Dismutase Enzymosomes: Carrier Capacity Optimization, in Vivo Behaviour and Therapeutic Activity. Pharmaceutical Research, 2015, 32, 91-102.	1.7	31
149	Hyperthermiaâ€Induced Drug Delivery from Thermosensitive Liposomes Encapsulated in an Injectable Hydrogel for Local Chemotherapy. Advanced Healthcare Materials, 2014, 3, 854-859.	3.9	64
150	Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treatment Reviews, 2014, 40, 578-584.	3.4	48
151	Passive versus Active Tumor Targeting Using RGD- and NGR-Modified Polymeric Nanomedicines. Nano Letters, 2014, 14, 972-981.	4.5	272
152	Hemocompatibility Assessment of two siRNA Nanocarrier Formulations. Pharmaceutical Research, 2014, 31, 3127-3135.	1.7	4
153	PEG-pHPMAm-based polymeric micelles loaded with doxorubicin-prodrugs in combination antitumor therapy with oncolytic vaccinia viruses. Polymer Chemistry, 2014, 5, 1674-1681.	1.9	17
154	Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: Comparison of the porcine and rat responses. Journal of Controlled Release, 2014, 195, 2-10.	4.8	79
155	Absolute MR thermometry using nanocarriers. Contrast Media and Molecular Imaging, 2014, 9, 283-290.	0.4	4
156	Anginex lipoplexes for delivery of anti-angiogenic siRNA. International Journal of Pharmaceutics, 2014, 472, 175-184.	2.6	8
157	Triggered Release of Doxorubicin from Temperature-Sensitive Poly(N-(2-hydroxypropyl)-methacrylamide mono/dilactate) Grafted Liposomes. Biomacromolecules, 2014, 15, 1002-1009.	2.6	52
158	Nanomedicines for Inflammatory Arthritis: Head-to-Head Comparison of Glucocorticoid-Containing Polymers, Micelles, and Liposomes. ACS Nano, 2014, 8, 458-466.	7.3	133
159	Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. Journal of Controlled Release, 2014, 182, 83-89.	4.8	83
160	Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. Journal of Controlled Release, 2014, 190, 624-636.	4.8	75
161	Thermally triggered release of a pro-osteogenic peptide from a functionalized collagen-based scaffold using thermosensitive liposomes. Journal of Controlled Release, 2014, 187, 158-166.	4.8	45
162	Immunoglobulin free light chains are biomarkers of poor prognosis in basal-like breast cancer and are potential targets in tumor-associated inflammation. Oncotarget, 2014, 5, 3159-3167.	0.8	34

#	Article	IF	Citations
163	Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget, 2014, 5, 6687-6700.	0.8	105
164	New Insights into the HIFU-Triggered Release from Polymeric Micelles. Langmuir, 2013, 29, 9483-9490.	1.6	17
165	In vivo nanotoxicity testing using the zebrafish embryo assay. Journal of Materials Chemistry B, 2013, 1, 3918.	2.9	104
166	Inhibition of Tumor Growth by Targeted Anti-EGFR/IGF-1R Nanobullets Depends on Efficient Blocking of Cell Survival Pathways. Molecular Pharmaceutics, 2013, 10, 3717-3727.	2.3	26
167	MRI of ICAM-1 Upregulation After Stroke: the Importance of Choosing the Appropriate Target-Specific Particulate Contrast Agent. Molecular Imaging and Biology, 2013, 15, 411-422.	1.3	50
168	Multidrug resistance: Physiological principles and nanomedical solutions. Advanced Drug Delivery Reviews, 2013, 65, 1852-1865.	6.6	220
169	Gold Nanocrystal Labeling Allows Low-Density Lipoprotein Imaging from the Subcellular to Macroscopic Level. ACS Nano, 2013, 7, 9761-9770.	7.3	77
170	Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 2013, 65, 1284-1298.	6.6	338
171	Complement activation by PEGylated liposomes containing prednisolone. European Journal of Pharmaceutical Sciences, 2013, 49, 265-271.	1.9	49
172	Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Current Opinion in Biotechnology, 2013, 24, 1159-1166.	3.3	279
173	Evidence for a new mechanism behind HIFU-triggered release from liposomes. Journal of Controlled Release, 2013, 168, 327-333.	4.8	56
174	Trends in polymeric delivery of nucleic acids to tumors. Journal of Controlled Release, 2013, 170, 209-218.	4.8	29
175	Intrinsically active nanobody-modified polymeric micelles for tumor-targeted combination therapy. Biomaterials, 2013, 34, 1255-1260.	5.7	111
176	Noninvasive Optical Imaging of Nanomedicine Biodistribution. ACS Nano, 2013, 7, 252-262.	7.3	102
177	Ocular pharmacoscintigraphic and aqueous humoral drug availability of ganciclovir-loaded mucoadhesive nanoparticles in rabbits. European Journal of Nanomedicine, 2013, 5, .	0.6	20
178	Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells. Clinical Cancer Research, 2013, 19, 1467-1475.	3.2	27
179	Nanomedicines as Cancer Therapeutics: Current Status. Current Cancer Drug Targets, 2013, 13, 362-378.	0.8	123
180	Liposomal Targeting of Prednisolone Phosphate to Synovial Lining Macrophages during Experimental Arthritis Inhibits M1 Activation but Does Not Favor M2 Differentiation. PLoS ONE, 2013, 8, e54016.	1.1	43

#	Article	IF	Citations
181	Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging. Methods in Enzymology, 2012, 508, 211-228.	0.4	26
182	Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting. Current Pharmaceutical Biotechnology, 2012, 13, 609-622.	0.9	36
183	Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes. International Journal of Pharmaceutics, 2012, 438, 209-216.	2.6	55
184	Personalized Nanomedicine. Clinical Cancer Research, 2012, 18, 4889-4894.	3.2	166
185	Combined treatment with recombinant tissue plasminogen activator and dexamethasone phosphateâ€containing liposomes improves neurological outcome and restricts lesion progression after embolic stroke in rats. Journal of Neurochemistry, 2012, 123, 65-74.	2.1	33
186	Application of cultured human regulatory TÂcells requires preclinical inÂvivo evaluation. Journal of Allergy and Clinical Immunology, 2012, 129, 852-855.e3.	1.5	6
187	Image-guided, targeted and triggered drug delivery to tumors using polymer-based microbubbles. Journal of Controlled Release, 2012, 163, 75-81.	4.8	133
188	Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. Journal of Controlled Release, 2012, 164, 87-94.	4.8	65
189	Nanoclusters of Iron Oxide: Effect of Core Composition on Structure, Biocompatibility, and Cell Labeling Efficacy. Bioconjugate Chemistry, 2012, 23, 941-950.	1.8	13
190	Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 2012, 7, 417.	3.3	22
191	GlucocorticoidâEŁoaded Coreâ€Crossâ€Linked Polymeric Micelles with Tailorable Release Kinetics for Targeted Therapy of Rheumatoid Arthritis. Angewandte Chemie - International Edition, 2012, 51, 7254-7258.	7.2	102
192	MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. European Journal of Pharmaceutical Sciences, 2012, 45, 436-441.	1.9	34
193	Liposomes as carriers for colchicine-derived prodrugs: Vascular disrupting nanomedicines with tailorable drug release kinetics. European Journal of Pharmaceutical Sciences, 2012, 45, 429-435.	1.9	32
194	Overcoming cellular multidrug resistance using classical nanomedicine formulations. European Journal of Pharmaceutical Sciences, 2012, 45, 421-428.	1.9	53
195	Polyplexes based on cationic polymers with strong nucleic acid binding properties. European Journal of Pharmaceutical Sciences, 2012, 45, 459-466.	1.9	45
196	Attaching the phage display-selected GLA peptide to liposomes: Factors influencing target binding. European Journal of Pharmaceutical Sciences, 2012, 45, 330-335.	1.9	27
197	Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. Journal of Controlled Release, 2012, 161, 175-187.	4.8	1,131
198	Critical factors in the development of tumor-targeted anti-inflammatory nanomedicines. Journal of Controlled Release, 2012, 160, 232-238.	4.8	20

#	Article	IF	Citations
199	Drug targeting systems for inflammatory disease: One for all, all for one. Journal of Controlled Release, 2012, 161, 225-234.	4.8	88
200	Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 2012, 159, 281-289.	4.8	83
201	Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. Journal of Controlled Release, 2012, 160, 88-95.	4.8	158
202	MRI-assessed therapeutic effects of locally administered PLGA nanoparticles loaded with anti-inflammatory siRNA in a murine arthritis model. Journal of Controlled Release, 2012, 161, 772-780.	4.8	55
203	Targeting tumor antigens to dendritic cells using particulate carriers. Journal of Controlled Release, 2012, 161, 25-37.	4.8	174
204	Physicochemical and Biological Evaluation of siRNA Polyplexes Based on PEGylated Poly(amido) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54	1.7	68
205	Comparison of Polymeric siRNA Nanocarriers in a Murine LPS-Activated Macrophage Cell Line: Gene Silencing, Toxicity and Off-Target Gene Expression. Pharmaceutical Research, 2012, 29, 669-682.	1.7	36
206	Macromolecular nanotheranostics for multimodal anticancer therapy. Nanoscale, 2011, 3, 4022.	2.8	12
207	Neovascular Age-Related Macular Degeneration. BioDrugs, 2011, 25, 171-189.	2.2	2
208	Liposomal Drug Formulations in the Treatment of Rheumatoid Arthritis. Molecular Pharmaceutics, 2011, 8, 1002-1015.	2.3	107
209	Development of a Cell-Selective and Intrinsically Active Multikinase Inhibitor Bioconjugate. Bioconjugate Chemistry, 2011, 22, 540-545.	1.8	18
210	Multifunctional Nanoemulsion Platform for Imaging Guided Therapy Evaluated in Experimental Cancer. ACS Nano, 2011, 5, 4422-4433.	7.3	183
211	Gene silencing activity of siRNA polyplexes based on biodegradable polymers. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 450-457.	2.0	38
212	A novel approach to identify non-palpable breast lesions combining fluorescent liposomes and magnetic resonance-guided high intensity focused ultrasound-triggered release. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 458-464.	2.0	7
213	Theranostic Nanomedicine. Accounts of Chemical Research, 2011, 44, 1029-1038.	7.6	765
214	Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity. Anti-Cancer Drugs, 2011, 22, 223-233.	0.7	87
215	A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy. International Journal of Nanomedicine, 2011, 6, 2697.	3.3	23
216	Endosomal escape pathways for delivery of biologicals. Journal of Controlled Release, 2011, 151, 220-228.	4.8	1,278

#	Article	IF	Citations
217	Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain. Journal of Controlled Release, 2011, 150, 30-36.	4.8	171
218	Anti-tumor activity of liposomal glucocorticoids: The relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. Journal of Controlled Release, 2011, 151, 10-17.	4.8	51
219	Nanobody â€" Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting. Journal of Controlled Release, 2011, 151, 183-192.	4.8	94
220	Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis. Journal of Controlled Release, 2011, 152, 363-369.	4.8	41
221	Reprint of "Nanobody â€" Shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting". Journal of Controlled Release, 2011, 153, 93-102.	4.8	29
222	Preparation and characterization of liposomal formulations of neurotensin-degrading enzyme inhibitors. International Journal of Pharmaceutics, 2011, 416, 448-452.	2.6	6
223	Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes. International Journal of Pharmaceutics, 2011, 416, 433-442.	2.6	278
224	SiRNA delivery with functionalized carbon nanotubes. International Journal of Pharmaceutics, 2011, 416, 419-425.	2.6	117
225	DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. International Journal of Pharmaceutics, 2011, 416, 426-432.	2.6	33
226	Safety of glucocorticoids can be improved by lower yet still effective dosages of liposomal steroid formulations in murine antigen-induced arthritis: Comparison of prednisolone with budesonide. International Journal of Pharmaceutics, 2011, 416, 493-498.	2.6	27
227	Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis. International Journal of Pharmaceutics, 2011, 416, 471-477.	2.6	51
228	In Vivo Methods to Study Uptake of Nanoparticles into the Brain. Pharmaceutical Research, 2011, 28, 456-471.	1.7	110
229	Disulfide-Based Poly(amido amine)s for siRNA Delivery: Effects of Structure on siRNA Complexation, Cellular Uptake, Gene Silencing and Toxicity. Pharmaceutical Research, 2011, 28, 1013-1022.	1.7	47
230	Multi-parametric assessment of the anti-angiogenic effects of liposomal glucocorticoids. Angiogenesis, 2011, 14, 143-153.	3.7	13
231	Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. Nature Reviews Cardiology, 2011, 8, 338-347.	6.1	63
232	Contribution of Classic and Alternative Effector Pathways in Peanut-Induced Anaphylactic Responses. PLoS ONE, 2011, 6, e28917.	1.1	52
233	Tumor vasculature as target for therapeutic intervention. Expert Opinion on Investigational Drugs, 2010, 19, 1321-1338.	1.9	19
234	Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today, 2010, 5, 197-212.	6.2	126

#	Article	IF	Citations
235	Identification of Peptide Ligands for Targeting to the Blood-Brain Barrier. Pharmaceutical Research, 2010, 27, 673-682.	1.7	62
236	Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release. Pharmaceutical Research, 2010, 27, 2569-2589.	1.7	791
237	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release, 2010, 141, 234-240.	4.8	67
238	Downregulation of EGFR by a novel multivalent nanobody-liposome platform. Journal of Controlled Release, 2010, 145, 165-175.	4.8	117
239	A method for quantifying cellular uptake of fluorescently labeled siRNA. Journal of Controlled Release, 2010, 148, 106-109.	4.8	32
240	Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. Journal of Controlled Release, 2010, 148, 303-310.	4.8	47
241	Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability. Experimental Hematology, 2010, 38, 282-291.	0.2	27
242	Longâ€Circulating and Passively Tumorâ€Targeted Polymerâ€Drug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy. Advanced Engineering Materials, 2010, 12, B413.	1.6	1
243	Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials, 2010, 31, 7797-7804.	5.7	241
244	Liposomes targeting tumour stromal cells. Molecular Membrane Biology, 2010, 27, 328-340.	2.0	7
245	Eradication of Medullary Multiple Myeloma by CD4+ Cytotoxic Human T Lymphocytes Directed at a Single Minor Histocompatibility Antigen. Clinical Cancer Research, 2010, 16, 5481-5488.	3.2	24
246	Nanomedicine formulations for combination therapies. Nano Reviews, 2010, 1, 5705.	3.7	12
247	HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine, 2010, 5, 1501-1523.	1.7	18
248	Therapeutic Nanomedicine: Cross linked micelles with transiently linked drugs â€“ a versatile drug delivery system. European Journal of Nanomedicine, 2010, 3, 19-24.	0.6	15
249	Synthetic vehicles for DNA vaccination. Journal of Drug Targeting, 2010, 18, 1-14.	2.1	26
250	Multimodal Clinical Imaging To Longitudinally Assess a Nanomedical Anti-Inflammatory Treatment in Experimental Atherosclerosis. Molecular Pharmaceutics, 2010, 7, 2020-2029.	2.3	144
251	Nanotheranostics and Image-Guided Drug Delivery: Current Concepts and Future Directions. Molecular Pharmaceutics, 2010, 7, 1899-1912.	2.3	344
252	Gene Silencing Activity of siRNA Polyplexes Based on Thiolated N,N,N-Trimethylated Chitosan. Bioconjugate Chemistry, 2010, 21, 2339-2346.	1.8	62

#	Article	IF	Citations
253	TAT-Peptide Modified Liposomes: Preparation, Characterization, and Cellular Interaction. Methods in Molecular Biology, 2010, 605, 349-359.	0.4	7
254	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. Human Gene Therapy, 2009, 20, 181-189.	1.4	54
255	Molecular imaging of tumor angiogenesis using Î±vÎ²3-integrin targeted multimodal quantum dots. Angiogenesis, 2009, 12, 17-24.	3.7	139
256	Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials, 2009, 30, 3466-3475.	5.7	219
257	Superparamagnetic Iron Oxide Nanoparticles Encapsulated in Biodegradable Thermosensitive Polymeric Micelles: Toward a Targeted Nanomedicine Suitable for Image-Guided Drug Delivery. Langmuir, 2009, 25, 2060-2067.	1.6	187
258	Targeted Delivery of Anti-Inflammatory Agents to Tumors. Current Pharmaceutical Design, 2009, 15, 1825-1843.	0.9	13
259	Sheddable Coatings for Long-Circulating Nanoparticles. Pharmaceutical Research, 2008, 25, 55-71.	1.7	510
260	Plasmid CpG Depletion Improves Degree and Duration of Tumor Gene Expression After Intravenous Administration of Polyplexes. Pharmaceutical Research, 2008, 25, 1654-1662.	1.7	25
261	Investigation into the Role of Tumor-Associated Macrophages in the Antitumor Activity of Doxil. Pharmaceutical Research, 2008, 25, 1948-1955.	1.7	32
262	Enzyme-induced shedding of a poly(amino acid)-coating triggers contents release from dioleoyl phosphatidylethanolamine liposomes. International Journal of Pharmaceutics, 2008, 355, 108-113.	2.6	24
263	Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells. International Journal of Pharmaceutics, 2008, 364, 258-264.	2.6	32
264	Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. Journal of Controlled Release, 2008, 127, 131-136.	4.8	37
265	Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release, 2008, 132, 200-207.	4.8	21
266	Utility of Targeted Glucocorticoids in Cancer Therapy. Journal of Liposome Research, 2008, 18, 47-57.	1.5	21
267	Antitumor Activity of Liposomal Prednisolone Phosphate Depends on the Presence of Functional Tumor-Associated Macrophages in Tumor Tissue. Neoplasia, 2008, 10, 108-117.	2.3	82
268	Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice. Journal of Steroid Biochemistry and Molecular Biology, 2008, 111, 101-110.	1.2	54
269	Biodegradable, Cationic Methacrylamide-Based Polymers for Gene Delivery to Ovarian Cancer Cells in Mice. Molecular Pharmaceutics, 2008, 5, 349-357.	2.3	21
270	Therapeutic nanomedicine: Liposomal corticosteroid as targeted antiinflammatory nanomedicine. European Journal of Nanomedicine, 2008, 1, .	0.6	1

#	Article	IF	Citations
271	Angiogenic endothelium shows lactadherin-dependent phagocytosis of aged erythrocytes and apoptotic cells. Blood, 2008, 111, 4542-4550.	0.6	61
272	Use of Radiolabeled Liposomes for Imaging of Infection and Inflammation. , 2008, , 237-251.		0
273	Bimodal Liposomes and Paramagnetic QD-Micelles for Multimodality Molecular Imaging of Tumor Angiogenesis. , 2008, , 487-512.		0
274	Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal, 2007, 21, 378-383.	0.2	82
275	Synthetic delivery systems for intravenous administration of nucleic acids. Nanomedicine, 2007, 2, 169-181.	1.7	12
276	Pharmacokinetics of poly(hydroxyethyl-l-asparagine)-coated liposomes is superior over that of PEG-coated liposomes at low lipid dose and upon repeated administration. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 737-743.	1.4	73
277	Photochemical internalization enhances silencing of epidermal growth factor receptor through improved endosomal escape of siRNA. Biochimica Et Biophysica Acta - Biomembranes, 2007, 1768, 1211-1217.	1.4	86
278	Targeting the retinal microcirculation to treat diabetic sight problems. Expert Opinion on Therapeutic Targets, 2007, 11, 1493-1502.	1.5	6
279	Temperature-Sensitive Poly(N-(2-hydroxypropyl)methacrylamide mono/dilactate)-Coated Liposomes for Triggered Contents Release. Bioconjugate Chemistry, 2007, 18, 2131-2136.	1.8	66
280	Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. International Journal of Pharmaceutics, 2007, 331, 167-175.	2.6	101
281	Poly(amino acid)s: Promising enzymatically degradable stealth coatings for liposomes. International Journal of Pharmaceutics, 2007, 331, 186-189.	2.6	82
282	Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes. International Journal of Pharmaceutics, 2007, 331, 211-214.	2.6	145
283	Quantitative Assessment of Human T Lymphocytes in RAG2â^'/â^'Î³câ^'/â^' Mice: The Impact of Ex Vivo Manipulation on In Vivo Functionality. Experimental Hematology, 2007, 35, 117-127.	0.2	11
284	Enzymosomes with surface-exposed superoxide dismutase: In vivo behaviour and therapeutic activity in a model of adjuvant arthritis. Journal of Controlled Release, 2007, 117, 186-195.	4.8	61
285	Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. Journal of Controlled Release, 2007, 117, 333-341.	4.8	109
286	Biodegradable Poly(2-Dimethylamino Ethylamino)Phosphazene for In Vivo Gene Delivery to Tumor Cells. Effect of Polymer Molecular Weight. Pharmaceutical Research, 2007, 24, 1572-1580.	1.7	59
287	Cytosolic Delivery of Liposomally Targeted Proteins Induced by Photochemical Internalization. Pharmaceutical Research, 2007, 24, 2040-2047.	1.7	37
288	Effect of Liposome Characteristics and Dose on the Pharmacokinetics of Liposomes Coated with Poly(amino acid)s. Pharmaceutical Research, 2007, 24, 2394-2401.	1.7	44

#	Article	IF	Citations
289	Effect of Intratumoral Injection on the Biodistribution, the Therapeutic Potential of HPMA Copolymer-Based Drug Delivery Systems. Neoplasia, 2006, 8, 788-795.	2.3	103
290	ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opinion on Drug Delivery, 2006, 3, 445-454.	2.4	19
291	Lanthanide-Loaded Liposomes for Multimodality Imaging and Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 520-527.	0.7	49
292	Quantum Dots with a Paramagnetic Coating as a Bimodal Molecular Imaging Probe. Nano Letters, 2006, 6, 1-6.	4.5	477
293	Annexin A5-Functionalized Bimodal Lipid-Based Contrast Agents for the Detection of Apoptosis. Bioconjugate Chemistry, 2006, 17, 741-749.	1.8	117
294	Annexin A5-Conjugated Quantum Dots with a Paramagnetic Lipidic Coating for the Multimodal Detection of Apoptotic Cells. Bioconjugate Chemistry, 2006, 17, 865-868.	1.8	141
295	1H NMR Spectroscopy as a Tool for Determining the Composition of Poly(hydroxyethyl-l-asparagine)-Coated Liposomes. Bioconjugate Chemistry, 2006, 17, 860-864.	1.8	13
296	Administration of prednisolone phosphate?liposomes reduces wound contraction in a rat partial-thickness wound model. Wound Repair and Regeneration, 2006, 14, 602-607.	1.5	15
297	Alveolar macrophages suppress non-specific inflammation caused by inhalation challenge with trimellitic anhydride conjugated to albumin. Archives of Toxicology, 2006, 80, 561-571.	1.9	13
298	Alveolar macrophages have a dual role in a rat model for trimellitic anhydride-induced occupational asthma. Toxicology and Applied Pharmacology, 2006, 211, 20-29.	1.3	14
299	Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. Journal of Controlled Release, 2006, 113, 1-8.	4.8	64
300	Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphateâ€“containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism, 2006, 54, 1198-1208.	6.7	164
301	Targeted Delivery of siRNA. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-9.	3.0	62
302	Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer. Journal of Liposome Research, 2006, 16, 185-194.	1.5	51
303	Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opinion on Biological Therapy, 2006, 6, 605-617.	1.4	54
304	Radiolabeling of Liposomes for Scintigraphic Imaging. , 2006, , 169-185.		2
305	Strategies for cytosolic delivery of liposomal macromolecules. International Journal of Pharmaceutics, 2005, 298, 305-309.	2.6	33
306	Application of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes for gene transfer into human ovarian carcinoma cells. International Journal of Pharmaceutics, 2005, 304, 185-192.	2.6	58

#	Article	IF	Citations
307	Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. Journal of Controlled Release, 2005, 103, 341-353.	4.8	286
308	Transporting silence: Design of carriers for siRNA to angiogenic endothelium. Journal of Controlled Release, 2005, 109, 5-14.	4.8	37
309	In vivo tumor transfection mediated by polyplexes based on biodegradable poly(DMAEA)-phosphazene. Journal of Controlled Release, 2005, 109, 275-287.	4.8	69
310	Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. Journal of Controlled Release, 2005, 110, 103-118.	4.8	125
311	Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis and Rheumatism, 2005, 52, 1314-1318.	6.7	133
312	Liposomes in the treatment of inflammatory disorders. Expert Opinion on Drug Delivery, 2005, 2, 465-476.	2.4	102
313	siRNA-mediated inhibition of angiogenesis. Expert Opinion on Biological Therapy, 2005, 5, 359-368.	1.4	11
314	Liposomal Targeting of Angiogenic Vasculature. Current Drug Delivery, 2005, 2, 363-368.	0.8	11
315	Coformulated N-Octanoyl-glucosylceramide Improves Cellular Delivery and Cytotoxicity of Liposomal Doxorubicin. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 704-710.	1.3	31
316	Tumor cell and tumor vasculature targeted liposomes for neutron capture therapy. Radiochimica Acta, 2005, 93, 589-593.	0.5	6
317	MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB Journal, 2005, 19, 2008-2010.	0.2	247
318	Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice. Neoplasia, 2005, 7, 118-127.	2.3	99
319	Enzymatic Degradation of Liposome-Grafted Poly(hydroxyethyl l-glutamine). Bioconjugate Chemistry, 2005, 16, 767-774.	1.8	35
320	Long-Circulating Sterically Stabilized Liposomes in the Treatment of Infections. Methods in Enzymology, 2005, 391, 228-260.	0.4	41
321	siRNA as a new drug: intellectual property. Expert Opinion on Therapeutic Patents, 2005, 15, 141-152.	2.4	1
322	CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis. Arthritis Research, 2005, 7, R604.	2.0	30
323	Targeting Antiâ€"Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ Perfusion. Journal of Cerebral Blood Flow and Metabolism, 2004, 24, 1193-1204.	2.4	146
324	Enhanced engraftment of human cells in RAG2/Î³c double-knockout mice after treatment with CL2MDP liposomes. Experimental Hematology, 2004, 32, 1118-1125.	0.2	35

#	Article	IF	Citations
325	Targeting liposomes to tumor endothelial cells for neutron capture therapy. Applied Radiation and Isotopes, 2004, 61, 963-967.	0.7	29
326	A Liposomal System for Contrast-Enhanced Magnetic Resonance Imaging of Molecular Targets. Bioconjugate Chemistry, 2004, 15, 799-806.	1.8	216
327	Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Research, 2004, 32, e149-e149.	6.5	800
328	OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochimica Et Biophysica Acta - Biomembranes, 2004, 1665, 48-56.	1.4	101
329	Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine, 2004, 22, 1903-1913.	1.7	181
330	In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharmaceutical Research, 2003, 20, 64-72.	1.7	65
331	Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate. Pharmaceutical Research, 2003, 20, 423-428.	1.7	39
332	A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- Î³c-/- double-mutant mice. Blood, 2003, 102, 2522-2531.	0.6	168
333	Targeted drug delivery systems for the intracellular delivery of macromolecular drugs. Drug Discovery Today, 2003, 8, 482-483.	3.2	56
334	Intravenous fate of poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. European Journal of Pharmaceutical Sciences, 2003, 20, 419-427.	1.9	49
335	Nanotechnological approaches for the delivery of macromolecules. Journal of Controlled Release, 2003, 87, 81-88.	4.8	101
336	Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. Journal of Controlled Release, 2003, 91, 115-122.	4.8	298
337	Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis and Rheumatism, 2003, 48, 2059-2066.	6.7	281
338	A Novel Family ofl-Amino Acid-Based Biodegradable Polymerâ˜Lipid Conjugates for the Development of Long-Circulating Liposomes with Effective Drug-Targeting Capacity. Bioconjugate Chemistry, 2003, 14, 1156-1164.	1.8	140
339	Drug targeting by longâ€circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126, 1895-1904.	3.7	190
340	Liposomes: From the Bench to the Bed. Journal of Liposome Research, 2003, 13, 33-36.	1.5	75
341	Radiolabeling of Liposomes for Scintigraphic Imaging. Methods in Enzymology, 2003, 373, 234-248.	0.4	17
342	TARGETED LIPOSOMES FOR DELIVERY OF PROTEIN-BASED DRUGS INTO THE CYTOPLASM OF TUMOR CELLS. Journal of Liposome Research, 2002, 12, 57-65.	1.5	25

#	Article	IF	Citations
343	LIPOSOME-ENABLED SYNERGISTIC INTERACTION OF ANTIMICROBIAL AGENTS. Journal of Liposome Research, 2002, 12, 121-127.	1.5	7
344	Endothelial Cells at Inflammatory Sites as Target for Therapeutic Intervention. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 161-171.	1.7	49
345	Functional Characterization of an Endosome-disruptive Peptide and Its Application in Cytosolic Delivery of Immunoliposome-entrapped Proteins. Journal of Biological Chemistry, 2002, 277, 27135-27143.	1.6	157
346	LIGAND-TARGETED LIPOSOMES DIRECTED AGAINST PATHOLOGICAL VASCULATURE. Journal of Liposome Research, 2002, 12, 129-135.	1.5	17
347	Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochimica Et Biophysica Acta - Biomembranes, 2002, 1564, 227-236.	1.4	102
348	Liposomes for Intravenous Drug Targeting: Design and Applications. Mini-Reviews in Medicinal Chemistry, 2002, 2, 319-329.	1.1	41
349	Long-circulating liposomes for i.v. targeted delivery of glucocorticoids in arthritis. Cellular and Molecular Biology Letters, 2002, 7, 291-2.	2.7	4
350	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity Implications in experimental and clinical oncology. Biochimica Et Biophysica Acta - General Subjects, 2001, 1526, 227-229.	1.1	26
351	Targeting influenza virosomes to ovarian carcinoma cells. FEBS Letters, 2001, 509, 71-76.	1.3	22
352	Therapeutic efficacy of liposomal gentamicin in clinically relevant rat models. International Journal of Pharmaceutics, 2001, 214, 103-105.	2.6	11
353	Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells. Cancer Gene Therapy, 2001, 8, 405-413.	2.2	39
354	Microscopic localization of PEG-liposomes in a rat model of focal infection. Journal of Controlled Release, 2001, 75, 347-355.	4.8	47
355	Therapeutic Efficacy of Liposome-Encapsulated Gentamicin in Rat Klebsiella pneumoniae Pneumonia in Relation to Impaired Host Defense and Low Bacterial Susceptibility to Gentamicin. Antimicrobial Agents and Chemotherapy, 2001, 45, 464-470.	1.4	30
356	Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. Journal of Antimicrobial Chemotherapy, 2001, 48, 333-344.	1.3	135
357	In Vivo Applications of PEG Liposomes: Unexpected Observations. Critical Reviews in Therapeutic Drug Carrier Systems, 2001, 18, 16.	1.2	61
358	Synovial macrophage depletion with clodronateâ€containing liposomes in rheumatoid arthritis. Arthritis and Rheumatism, 2000, 43, 1951-1959.	6.7	198
359	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. Pharmaceutical Research, 2000, 17, 600-606.	1.7	44
360	Lyophilization of TC-99m-Hynic Labeled Peg-Liposomes. Journal of Liposome Research, 2000, 10, 117-129.	1.5	9

#	Article	IF	Citations
361	Targeting of Antibiotics in Bacterial Infections Using Pegylated Long-Circulating Liposomes. Journal of Liposome Research, 2000, 10, 513-521.	1.5	8
362	Localization of sterically stabilized liposomes in experimental rat Klebsiella pneumoniae pneumonia: dependence on circulation kinetics and presence of poly(ethylene)glycol coating. Biochimica Et Biophysica Acta - Biomembranes, 2000, 1468, 253-261.	1.4	41
363	Tc-99m-PEG-Liposomes for the Evaluation of Colitis in Crohn's Disease. Journal of Drug Targeting, 2000, 8, 225-233.	2.1	60
364	Effects of Physicochemical Characteristics of Poly(2-(dimethylamino)ethyl methacrylate)-Based Polyplexes on Cellular Association and Internalization. Journal of Drug Targeting, 2000, 8, 51-66.	2.1	87
365	Liposomes for Local Sustained Drug Release. , 2000, , 137-180.		5
366	Liposomes for scintigraphic detection of infection and inflammation. Advanced Drug Delivery Reviews, 1999, 37, 225-235.	6.6	75
367	Immunoliposomes for the targeted delivery of antitumor drugs. Advanced Drug Delivery Reviews, 1999, 40, 103-127.	6.6	163
368	Comparative transfection studies of human ovarian carcinoma cellsin vitro,ex vivo andin vivo with poly(2-(dimethylamino)ethyl methacrylate)-based polyplexes. Journal of Gene Medicine, 1999, 1, 156-165.	1.4	59
369	Cationic polymeric gene delivery of Î²-glucuronidase for doxorubicin prodrug therapy. Journal of Gene Medicine, 1999, 1, 407-414.	1.4	20
370	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1419, 325-334.	1.4	101
371	Localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue: influence of liposome characteristics. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1421, 329-339.	1.4	51
372	The Design of a Pharmaceuttcally Acceptable Liposomal Formulation of Recombinant Interleukin-2 (Ril-2) for Locoregional Anticancer Immunotherapy. Journal of Liposome Research, 1999, 9, 313-329.	1.5	4
373	Imaging Experimental Intraabdominal Abscesses With 99mTc-PEG Liposomes and 99mTc-HYNIC IgG. Annals of Surgery, 1999, 229, 551-557.	2.1	30
374	Interaction of Recombinant Interleukin-2 with Liposomal Bilayers. Journal of Pharmaceutical Sciences, 1998, 87, 707-714.	1.6	21
375	Liposomes: quo vadis?. Pharmaceutical Science & Technology Today, 1998, 1, 19-31.	0.7	164
376	Development of a routine analysis method for liposome encapsulated recombinant interleukin-2. Biomedical Applications, 1998, 716, 285-291.	1.7	11
377	Stealthâ„¢ Therapeutic Systems: Rationale and Strategies. , 1998, , 25-34.		0
378	Lymphatic Uptake and Biodistribution of Liposomes after Subcutaneous Injection I. Influence of the Anatomical Site of Injection. Journal of Liposome Research, 1997, 7, 85-99.	1.5	33

#	Article	IF	Citations
379	Liposome-mediated peptide loading of MHC-DR molecules in vivo. FEBS Letters, 1997, 409, 91-95.	1.3	18
380	Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific activation of anticancer prodrugs. Advanced Drug Delivery Reviews, 1997, 24, 225-231.	6.6	17
381	Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). , 1997, 14, 1479-1484.		83
382	Targeted delivery of diphtheria toxin via immunoliposomes: efficient antitumor activity in the presence of inactivating anti-diphtheria toxin antibodies. FEBS Letters, 1996, 395, 245-250.	1.3	10
383	Biosynthetically lipid-modified human scFv fragments from phage display libraries as targeting molecules for immunoliposomes. FEBS Letters, 1996, 399, 232-236.	1.3	24
384	Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharmaceutical Research, 1996, 13, 604-610.	1.7	36
385	Opportunities in targeted drug delivery to Kupffer cells: delivery of immunomodulators to Kupffer cells-activation of tumoricidal properties. Advanced Drug Delivery Reviews, 1995, 17, 21-30.	6.6	12
386	Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews, 1995, 17, 31-48.	6.6	788
387	Novel developments in liposomal delivery of peptides and proteins. Journal of Controlled Release, 1995, 36, 19-24.	4.8	30
388	Sterically stabilized amphotericin B-liposomes: toxicity and biodistribution in mice. Journal of Controlled Release, 1995, 37, 123-129.	4.8	32
389	Design of immunoliposomes directed against human ovarian carcinoma. Biochimica Et Biophysica Acta - Biomembranes, 1995, 1235, 126-139.	1.4	32
390	Liposomal Delivery of Peptides and Proteins. Journal of Liposome Research, 1995, 5, 481-489.	1.5	3
391	Immunoliposomes in Vivo. ImmunoMethods, 1994, 4, 259-272.	0.8	53
392	Targeting of peptide and protein drugs. European Journal of Pharmaceutical Sciences, 1994, 2, 17-18.	1.9	6
393	Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1992, 1138, 318-326.	1.8	80
394	Prolonged systemic delivery of peptide drugs by long-circulating liposomes: illustration with vasopressin in the Brattleboro rat. Pharmaceutical Research, 1992, 09, 260-265.	1.7	70
395	Liposomes and biotherapeutics. Biotherapy (Dordrecht, Netherlands), 1991, 3, 25-42.	0.7	41
396	Processing of Doxorubicin-Containing Liposomes by Liver Macrophages in Vitro. Journal of Liposome Research, 1989, 1, 195-210.	1.5	12

#	Article	IF	Citations
397	Immunoliposomes in vivo: state of the art. Advanced Drug Delivery Reviews, 1988, 1, 249-266.	6.6	40
398	The interaction of cytostatic drugs with adsorbents in aqueous media. The potential implications for liposome preparation. Biochimica Et Biophysica Acta - Biomembranes, 1985, 818, 343-351.	1.4	45